ANP Technologies, Inc.
ANP Technologies, Inc. is a world leader in developing innovative nanobiotechnology-based products for applications related to immunogenicity, biodefense, biologic drug development/testing, medical diagnostics, and food safety testing. The company focuses on nanotherapeutics, rapid biothreat detection, and bioanalytical methods, with a mission to contribute to health, safety, and defense through advanced nanotechnology solutions.
Industries
Nr. of Employees
small (1-50)
ANP Technologies, Inc.
Patents
Rapid tests for the detection of inhibitors of enzymes and human exposure to the same
US-10458916-B2
View Details
Rapid tests for the detection of inhibitors of enzymes and human exposure to the same
US-10458916-B2
View DetailsProducts
Multiplexed rapid lateral-flow biothreat detection kits
Assay strips configured for 1-, 2-, 5- or 10-plex detection of bacterial, viral and toxin targets in powders, environmental samples and aqueous matrices; designed to minimize hook-effect and enable small-volume sampling.
Handheld and automated optical readers (portable and autoreader)
Portable palm-sized readers and automated readers for scanning lateral-flow assays, performing quantitative analysis, storing images/results on removable media, and exporting data to PC.
High-sensitivity streptavidin/neutravidin ELISA plates with nano-orientation coating
Coated 96-well plates using nanoscale orientation chemistry to increase active coating efficiency for biotinylated molecules and enhance assay sensitivity while reducing reagent consumption.
Protein extraction / interfering-protein removal kits (nanoparticle-based)
Kits to prepare or supply functionalized nanoparticles that scavenge and remove endogenous interfering proteins from biological matrices prior to PK or immunogenicity assays, improving accuracy and reducing reagent use.
Immunogenicity ELISA kit and rapid immunogenicity lateral-flow assay
ELISA-based and rapid point-of-care kits for detection of anti-PEG and other anti-drug antibodies including positive control antibodies and reagents, with documented limits of detection and recommended storage conditions.
Protein labeling kits (biotinylation and digoxigenin labeling)
Do-it-yourself kits for conjugating biotin, digoxigenin or fluorescein to proteins with rapid QC strips, enabling construction of sandwich PK and immunogenicity assays.
Multiplexed rapid lateral-flow biothreat detection kits
Assay strips configured for 1-, 2-, 5- or 10-plex detection of bacterial, viral and toxin targets in powders, environmental samples and aqueous matrices; designed to minimize hook-effect and enable small-volume sampling.
Handheld and automated optical readers (portable and autoreader)
Portable palm-sized readers and automated readers for scanning lateral-flow assays, performing quantitative analysis, storing images/results on removable media, and exporting data to PC.
High-sensitivity streptavidin/neutravidin ELISA plates with nano-orientation coating
Coated 96-well plates using nanoscale orientation chemistry to increase active coating efficiency for biotinylated molecules and enhance assay sensitivity while reducing reagent consumption.
Protein extraction / interfering-protein removal kits (nanoparticle-based)
Kits to prepare or supply functionalized nanoparticles that scavenge and remove endogenous interfering proteins from biological matrices prior to PK or immunogenicity assays, improving accuracy and reducing reagent use.
Immunogenicity ELISA kit and rapid immunogenicity lateral-flow assay
ELISA-based and rapid point-of-care kits for detection of anti-PEG and other anti-drug antibodies including positive control antibodies and reagents, with documented limits of detection and recommended storage conditions.
Protein labeling kits (biotinylation and digoxigenin labeling)
Do-it-yourself kits for conjugating biotin, digoxigenin or fluorescein to proteins with rapid QC strips, enabling construction of sandwich PK and immunogenicity assays.
Services
Preparation of nanoparticles functionalized with customer-supplied or provided binding agents for targeted removal of interfering endogenous proteins and for custom sample-prep workflows.
Support for ELISA and rapid lateral-flow immunogenicity assay design, kit configuration, positive-control reagents, and comparative validation with centralized methods.
Volume manufacturing, packaging, and delivery of multiplexed rapid assay kits and associated sampling kits under government contract vehicles.
Provision of handheld and automated reader hardware, software for result interpretation and data management, plus technical support for field troubleshooting and operator training.
Collaborative licensing and co-development arrangements with academic centers and commercial partners to advance targeted therapies and nanoformulated drugs toward clinical development.
Preparation of nanoparticles functionalized with customer-supplied or provided binding agents for targeted removal of interfering endogenous proteins and for custom sample-prep workflows.
Support for ELISA and rapid lateral-flow immunogenicity assay design, kit configuration, positive-control reagents, and comparative validation with centralized methods.
Volume manufacturing, packaging, and delivery of multiplexed rapid assay kits and associated sampling kits under government contract vehicles.
Provision of handheld and automated reader hardware, software for result interpretation and data management, plus technical support for field troubleshooting and operator training.
Collaborative licensing and co-development arrangements with academic centers and commercial partners to advance targeted therapies and nanoformulated drugs toward clinical development.
Expertise Areas
- Nanoparticle drug delivery and formulation
- Rapid lateral-flow immunoassay development (multiplex formats)
- Biodefense and biothreat detection
- Immunogenicity testing and assay development
Key Technologies
- Nanoencapsulation / nanoparticle drug delivery
- Poly(2-oxazoline)-based polymer excipients (polymer excipients for nanoformulations)
- Lateral-flow immunoassays (multiplexed)
- Nanoparticle-based protein extraction / sample cleanup
News & Updates
Certification demonstrating ANP's commitment to quality in development and manufacturing.
Recognition from SBA for technological innovation in biodefense and biotherapeutics.
Regulatory approval for ANP's cancer drug candidate FID-007.
Collaborative development of targeted leukemia therapies leveraging nanotechnology.
Achieved certification for quality management system in 2013.
Received in 2011 for innovation in biodefense technology.
Certification demonstrating ANP's commitment to quality in development and manufacturing.
Recognition from SBA for technological innovation in biodefense and biotherapeutics.
Regulatory approval for ANP's cancer drug candidate FID-007.
Collaborative development of targeted leukemia therapies leveraging nanotechnology.
Achieved certification for quality management system in 2013.
Received in 2011 for innovation in biodefense technology.